References
- Abal M, Bras-Goncalves R, Judde JG, Fshihi H, De Cremoux P, Louvard D, Magdelenat H, Robine S, Poupon MF. 2004. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene. 23: 1737-1744. https://doi.org/10.1038/sj.onc.1207299
- Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. 2001. Taxolinduced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 20:147-155. https://doi.org/10.1038/sj.onc.1204062
- Bahadori HR, Green MR, Catapano CV. 2001. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 48:188-196. https://doi.org/10.1007/s002800100327
- Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S. 2009. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for color ectal liver metastases. BMC Cancer. 9: 156. https://doi.org/10.1186/1471-2407-9-156
- Borbe R, Riger J, Weller M. 1999. Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. Cancer Chemother Pharmacol. 44: 217-227. https://doi.org/10.1007/s002800050970
- Chen YG, Cipriano SC, Arenkiel JM, Miller FR. 1995. Tumor suppressing by p21WAF1 undergo normal development but are defective in G I checkpoint control. Cell. 82: 675-784. https://doi.org/10.1016/0092-8674(95)90039-X
- Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, De Cesaris P, Zani BM. 2005. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiationand onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer. 4:41. https://doi.org/10.1186/1476-4598-4-41
- Cui X, Zhang J, Ma P, Myers DE, Goldberg IG, Sittler KJ, Barb JJ, Munson PJ, Cintron AP, McCoy JP, ct al. 2005. cGMP-independent nitric oxide signaling and regulation of the cell cycle. BMC Genomics. 6:151. https://doi.org/10.1186/1471-2164-6-151
- Deacon K, Mistry P, Chernoff J, Blank JL, Patel R. 2003. p38 mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates dell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell. 14: 2071-2087. https://doi.org/10.1091/mbc.E02-10-0653
- Downes CS, Mullinger AM, Johnson RT. 1991. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc. Nati. Acad. Sci USA. 88: 8895-8899. https://doi.org/10.1073/pnas.88.20.8895
- Fishman AD, Wadler S. 2001. Advances in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 1: 20-35. https://doi.org/10.3816/CCC.2001.n.002
- Fuchs C, Mitchell EP, Hoff PM. 2006. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 32: 491-503. https://doi.org/10.1016/j.ctrv.2006.07.001
-
Furuta T, Hayward RL, Meng LH, Takemura H, Aune GJ, Bonner WM, Aladjem MI, Kohn KW, Pommier Y. 2006.
$p21^{CDKNIA}$ allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydro xystaurosporine. Oncogene. 25: 2839-2849. https://doi.org/10.1038/sj.onc.1209313 - Giannakakou P, Robey R, Fojo T, Blagosklonny MY. 2001. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 20: 3806-3813. https://doi.org/10.1038/sj.onc.1204487
- Gupta M, Fan S, Zhan O, Kohn KW, O'Connor PM, Pommier Y. 1997. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res. 3: 1653-1660.
- Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, Hendrickson EA, Balan KV, Pantazis P, Wyche JH. 2002. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem. 77: 17154-17160.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics. CA Cancer J Clin. 58: 71-96. https://doi.org/10.3322/CA.2007.0010
- Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK. 1996. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 88: 734 741. https://doi.org/10.1093/jnci/88.11.734
- Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. 1994. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86: 441-446. https://doi.org/10.1093/jnci/86.6.441
- Manfredi JJ, Parness J, Horwitz SB. 1982. Taxol binds to cellular microtubules. J Cell Biol. 94: 688-696. https://doi.org/10.1083/jcb.94.3.688
- Pommier Y. 2006. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 6: 789-802. https://doi.org/10.1038/nrc1977
- Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, Antony S, Meng L, Liao Z, Kohlhagen G, et al. 2003. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res. 532: 173-203. https://doi.org/10.1016/j.mrfmmm.2003.08.016
- Satou M, Aizawa S, Hayakari M, Ookawa K, Tsuchida S. 2003. Enhanced sensitivity to cis-diamminedichloro-platinum(II) of a human carcinoma cell line with mutated p53 gene by cycIin-dependent kinase inhibitor p21WAF1 expression. Cancer Sci. 94:286-291. https://doi.org/10.1111/j.1349-7006.2003.tb01434.x
- Schmidt F, Schuster M, Streffer J, Schabet M, Weller M. 1999. Topotecan-based combination chemotherapy for human malignant glioma. Anticancer Res. 19:1217-1221.
- Segal NH, Saltz LB. 2009. Evolving treatment of advanced colon cancer. Annu Rev Med. 60: 207-219. https://doi.org/10.1146/annurev.med.60.041807.132435
- Shamu CE, Murray AW. 1992. Sister chromatid separation in frog egg extracts requires DNA topoisomerase II activity during anaphase. J Cell Biol. 117: 921-934. https://doi.org/10.1083/jcb.117.5.921
- Sinicrope FA, Roddey G, Lemoine M, Ruan S, Stephens LC, Frazier ML, Shen Y, Zhang W. 1998. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasia but not hereditary nonpolyposis colorectal cancers. Clin Cancer Res. 4: 1251-1261.
- Tishler RB, Schiff PB, Geard CR, Hall EJ. 1992. Taxol: a novel radiation sensitizer. Int J Radiat Oncol BioI Phys. 22: 613-617. https://doi.org/10.1016/0360-3016(92)90888-O
- Torres K, Horwitz SB. 1998. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res. 58: 3620-3626.
- Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J Am Chem Soc. 88: 3888-3890. https://doi.org/10.1021/ja00968a057
- Wolpin BM, Mayer RJ. 2008. Systemic treatment of colorectal cancer. Gastroenterology. 134: 1296-1310. https://doi.org/10.1053/j.gastro.2008.02.098
- Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. 1995. p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med. 1: 1052-1056. https://doi.org/10.1038/nm1095-1052
- Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN. 2002. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 62: 1688-1695.
Cited by
- Anti-inflammatory actions of plant-derived multiple monoclonal antibody CO17-1A × BR55 related with anti-cancer effects in AOM/DSS-induced colorectal cancer mouse via down-regulating of ERK1/2 vol.20, pp.4, 2016, https://doi.org/10.1080/19768354.2016.1211176